biosimilars
基本解释
- 生物仿制药
英汉例句
- Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
生物仿制制药是对生物技术制药进行的非专利仿制（尽管不是完全一致的复制）。 - Michael Kamarck of Merck, an American drugs firm which moved into biosimilars in 2008, thinks the barriers to entry are so great that “only a handful” of firms will be able to pull it off.
一家于2008年转向生物仿制制药的美国制药公司---默克公司认为进入生物仿制制药这个领域的障碍是如此之大以至于“只有几家”公司有能力成功进入。 - This will put Merck in direct competition both with generics firms, such as Teva of Israel, and with biotech giants, such as Amgen, which make the expensive products that biosimilars hope to replace.
默克将因此与仿制药公司（比如以色列的Teva）和生物技术业的巨头（比如Amgen）直接竞争，生物仿制品有望替代这些公司生产的昂贵产品。 - In the future, new analytical methods will facilitate the development and regulatory approval of biosimilars.
FORBES: Do You Think 'Biosimilars' Will Reduce Healthcare Expenditures? Think again. - Concurrently, over the past few years the broader view of the biosimilars market has changed.
FORBES: Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars - When these arguments were made during the debate over creating a biosimilars pathway, they were often dismissed.
FORBES: Blood Drug Woes Could Weigh on FDA and its Approval of New, Copycat Biologic Medicines